Why the study?
What is the incidence and what are the predictors of venous thromboembolic events associated with central venous port insertion in cancer patients?
Population
1097 consecutive cancer patients undergoing chemotherapy with first central venous port (CVP) implantation
Design
Cohort
Follow-up
12 months
Authors
Loading...
Substantial VTE risk after CVP insertion in cancer patients warrants caution; leaves open whether targeted prophylaxis in high Khorana or lung cancer subgroups improves outcomes.
What is the incidence and what are the predictors of venous thromboembolic events associated with central venous port insertion in cancer patients?
Central venous port insertion in cancer patients carries a significant risk of VTE, with high Khorana risk score and lung cancer identifying a high-risk subgroup that may benefit from targeted thromboprophylaxis.
Moinat et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: